retatrutide ly3437943 clinical trial results vs Tirzepatide (2026): Differences in Weight Loss, Metabol – Revolution Health & Wellness Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

Long-Term Outlook Patients often see meaningful weight loss in the first few months, but results vary

The medication starts at 2.5mg and escalates through 5mg, 7.5mg, 10mg, 12.5mg, and up to 15mg

Find articles by Locatelli, C

Gradual tapering over 4-8 weeks may reduce the severity of appetite rebound compared to abrupt discontinuation, allowing your body's hunger-regulation system to adjust more gently

Measurements of worse eyes were used for statistical analysis, i.e., higher pRNFL thickness as a marker of oedema and lower GCL volume as a marker of neuroaxonal loss

But you reported that the global peptide market has now swelled to more than $50 billion in annual sales, and is projected to nearly double again in roughly the next decade